Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis

Pons, M, Georgiadis, S, Østergaard, M, Ahmadzay, Z F, Glintborg, B, Heberg, J, Christensen, S N, Rasmussen, S H, Loft, A G, Castrejon, I, Sánchez-Alonso, F, Iannone, F, Nordström, D, Hokkanen, A-M, Ciurea, A, Nissen, M J, Zavada, J, Pavelka, K, Rotar, Z, Pirkmajer, K P, Michelsen, B, Mielnik, P, Bernardes, M, Khmelinskii, N, Laas, K, Vorobjov, S, Codreanu, C, Macfarlane, G J, Jones, G, Gudbjornsson, B, Palsson, O, Wallman, J K, van der Horst-Bruinsma, I E, Onen, F, Hetland, M L & Ørnbjerg, L M 2025, 'Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis', Joint, Bone,Spine, vol. 92, no. 3, 105824. https://doi.org/10.1016/j.jbspin.2024.105824